Previous studies have shown that proton magnetic resonance spectroscopy (MRS) is useful in predicting neurologic prognosis in children with traumatic brain injury (TBI). Reductions in N-acetyl derived metabolites and presence of lactate have been predictive of poor outcomes. We examined another spectroscopy metabolite, myoinositol (mI), to determine whether it is altered after TBI. Found primarily in astrocytes, mI functions as an osmolyte and is involved in hormone response pathways and protein-kinase C activation. Myoinositol is elevated in the newborn brain and is increased in a variety of diseases. We studied 38 children (mean age 11 y; range 1.6 -17 y) with TBI using quantitative short echo time occipital gray and parietal white matter proton MRS at a mean of 7 d (range 1-17 d) after injury. We found that occipital gray matter mI levels were increased in children with TBI (4.30 Ϯ 0.73) compared with controls (3.53 Ϯ 0.48; p ϭ 0.003). We also found that patients with poor outcomes 6 -12 mo after injury had higher mI levels (4.78 Ϯ 0.68) than patients with good outcomes (4.15 Ϯ 0.69; p Ͻ 0.05). Myoinositol is elevated after pediatric TBI and is associated with a poor neurologic outcome. The reasons for its elevation remain unclear but may be due to astrogliosis or to a disturbance in osmotic function. Over the past decade, proton magnetic resonance spectroscopy (MRS) has been proven helpful in evaluating adults and children with traumatic brain injury (TBI) (1,2). Reductions in the neuronal marker N-acetyl aspartate (NAA) and in creatine (Cre), a marker of cell energy metabolism, as well as increases in choline (Cho), an indicator of membrane disruption, occur within the first several days. In adults, the magnitude of these metabolite changes correlate with the severity of injury and also with neurologic and neuropsychological outcomes (3,4). Our previous studies in children have also confirmed these findings (5,6).
Over the past decade, proton magnetic resonance spectroscopy (MRS) has been proven helpful in evaluating adults and children with traumatic brain injury (TBI) (1, 2) . Reductions in the neuronal marker N-acetyl aspartate (NAA) and in creatine (Cre), a marker of cell energy metabolism, as well as increases in choline (Cho), an indicator of membrane disruption, occur within the first several days. In adults, the magnitude of these metabolite changes correlate with the severity of injury and also with neurologic and neuropsychological outcomes (3, 4) . Our previous studies in children have also confirmed these findings (5, 6) .
Myoinositol (mI) is another metabolite that can be detected using short echo time spectroscopy. Myoinositol is found primarily in astrocytes and functions as a marker of astrocytic activity. It serves as an osmolyte, and is involved in phosphoinositide-mediated signal transduction. Myoinositol as detected by MRS has been shown to be elevated in the newborn brain and is increased in Alzheimer's disease, renal failure, diabetes mellitus, bipolar disease, use of lithium, hypoxia, hyperosmolar states, in some patients with Canavan disease and after severe neonatal encephalopathy (7, 8) . It may be decreased in chronic hepatic encephalopathies, stroke, tumor, infection and low-grade malignancies.
Within the first hours after TBI, the complex process referred to as reactive astrocytosis, astrogliosis, or glial scarring begins (9) . After the initial injury, which is accompanied by neuronal and glial cell death, followed later by apoptotic cell loss, recruitment of microglia and peripheral monocytes occurs. Nestin-positive progenitor cells differentiate into astrocytes at the site of injury and within 3 to 5 d the process of reactive astrocytosis begins to surround the area of injury. While it remains controversial whether the process of astrogliosis that results in a glial scar is ultimately beneficial or detrimental to the degree of cerebral recovery, it is clear that astrocytes play an important role in the evolution of this process both in the mature and developing nervous system (9, 10) .
In the current study we examined the role of mI in 38 children with TBI. These patients also all had evidence of diffuse axonal injury (DAI) detected by a new gradient echo magnetic resonance imaging (MRI) technique known as susceptibility weighted imaging (SWI) recently found useful in detecting hemorrhagic lesions associated with DAI (11) . We were interested in determining if children with DAI had alterations in mI, as a possible marker of astrocytic activity or as a marker of altered osmolar function and whether this correlated with clinical and spectroscopy variables as well as 6 -12 mo neurologic outcomes. We were also interested in determining if there was a relation between changes in the spectral metabolite Glx (glutamate/glutamine) as studies in adult TBI patients (12, 13) and in children with nonaccidental trauma (14) have shown that glutamate as measured in ventricular cerebrospinal fluid by microdialysis is increased.
METHODS
Patient selection and data collection. We studied 38 children and adolescents with TBI and presumed DAI admitted to the pediatric or adult intensive care units at Loma Linda University Medical Center between March, 2001 and September, 2002. The study population was a nonconsecutive series of patients with a well-documented history of TBI who were clinically suspected to be at high risk for long-term neurologic impairment. Patients were considered at high risk if they did not show significant recovery within the first day after admission. We excluded children with a history of known CNS malformation, developmental disability, previous brain injury, or age younger than one month. A neurosurgeon or neurologist examined all children before the MRI study. These children were also part of a larger ongoing study, examining the role of magnetic resonance spectroscopy (MRS) for outcome prediction in children and adolescents with various forms of acute CNS insults, which was approved by the Institutional Review Board of Loma Linda University Medical Center.
Clinical variables determined included age, initial Glasgow Coma Scale (GCS) score, first determined mean arterial blood pressure (MAP), heart rate, arterial blood pH, hematocrit, serum glucose and sodium levels, occurrence of cardiac arrest or presence of fixed dilated pupils, initial intracranial pressure (ICP) level if monitored, occurrence of seizures, days in coma, on ventilator, and in hospital, and discharge outcome and outcome 6 to 12 mo after injury as determined by the Pediatric Cerebral Category Performance Scale score (15) . The PCPCS is a six-point outcome scoring system modified from the Glasgow Outcome Scale (GOS) score. It quantifies the overall functional morbidity and cognitive impairment of infants and children, has been validated in pediatric patients after acute CNS injuries and recently has been shown to correlate with other measures of psychometric function (16) . The score includes the following outcomes: (1) normal: can perform all age-appropriate activities; (2) mild disability: conscious, alert and able to interact at most age-appropriate activities and may have mild neurologic deficit; (3) moderate disability: conscious, sufficient cerebral function for age-appropriate activities of daily life, but has significant cognitive impairment; (4) severe disability: conscious, dependent on others for daily support because of impaired brain function; (5) persistent vegetative state (PVS); and (6) death. For the purpose of analysis, the six PCPCS scores were dichotomized into two groups: (1) normal or mild disability and (2) moderate, severe disability or vegetative state. There were no patients who died.
A group of 10 control patients seen during the same time period of the study were used so that we could compare the MRS results of the TBI patients with normative data. Three controls were normal volunteers who did not require sedation. The other controls were patients who had neuroimaging done for evaluation of clinical neurologic or craniofacial disorders (e.g. headaches, facial hemangiomas, isolated seizure, etc) and were neurologically normal on examination.
MR imaging. When medically stable, children were transported to the MR scanner and were monitored during these studies by intensive care unit and radiology personnel. All studies were performed on a 1.5T whole body imaging system using a standard quadrature head coil (Siemens Medical Solutions, Vision, Numaris VB33D, Iselin, NJ).
MRI sequences included sagittal T1 weighted scans (TR/TE ϭ 500/14 ms, 5 mm thick, 20% gap), axial and coronal fast T2 weighted scans (TR/TE ϭ 3500/90 ms, 5 mm thick/ 40% gap), and axial 3D gradient echo susceptibility weighted scans (TR/TE ϭ 57/40 ms, flip angle ϭ 20°, 32 partitions of 2 mm thick). These scans were used for comparison with the information available on SWI images. The SWI sequence consisted of a strongly susceptibility-weighted, low-bandwidth (78 Hz/ pixel) 3D-FLASH sequence (TR/TE ϭ 57/40 ms, FA ϭ 20°) with first-order flow compensated in all 3 orthogonal directions. Thirty-two partitions of 2 mm were acquired using a rectangular FOV (5/8 of 256 mm) and a matrix size of 160 ϫ 512, resulting in a voxel size of 1 ϫ 0.5 ϫ 2 mm 3 . The SWI sequence included the majority of the cerebral hemispheres and the posterior fossa, with an acquisition time of approximately 9.5 min. SWI images were created using the magnitude and phase images as previously described (11, 17) . Hemorrhagic lesions were defined as hypointense foci that were not compatible with vascular, bony or artifactual structures on conventional GRE or SWI. Hemorrhagic shearing lesions of the entire cranium were counted individually on SWI sequences. Because hemorrhagic lesions were variable in shape, images were then analyzed using a computer software program (Image Pro Plus, Media Cybernetics Inc.) to automatically count the number and calculate the area and volume of lesions (expressed as mm 3 ).
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MR Spectroscopy. Two single voxel proton spectra were acquired with 8 mL volumes in normal appearing brain; one in the occipital gray matter (OGM) located in a paramedian position across the interhemispheric fissure and a second in the parieto-occipital white matter (PWM) placed in the right or left hemisphere to avoid obvious areas of injury. Previous studies have shown that measurements from these locations produce accurate long-term outcome predictions (2, 3, 18) . To predict global injury, we felt that it was important not to acquire spectra from brain with obvious hemorrhage or contusion because larger spectral changes produced in these focal areas of injury would tend to overestimate the total amount of injury and ultimately produce false positive predictions. A watersuppressed stimulated echo acquisition mode (STEAM) sequence was used with TR/TE/TM ϭ 3000/20/13 ms and 128 NEX, following manual localized shimming to achieve water line widths less than 8 Hz. A reference spectrum was acquired with identical acquisition parameters and 8 acquisitions to use for eddy current correction. Metabolite levels for NAA, Cre, Cho, mI, and Glx (glutamate/glutamine) for each of the 38 patients were quantitatively measured using a Linear Combination of Model in vitro spectra, (LCModel), an automatic (user independent), frequency-domain fitting routine. The method employs a basis set of concentration calibrated model spectra of individual metabolites to estimate absolute concentrations of similar brain metabolites from in vivo spectral data correcting for residual eddy current effects and actual coil loading by using the transmitter reference amplitude (19) . This method offers several advantages. It allows for distinction between metabolites with overlapping signals to yield individual concentrations as well as providing summation data for overlapping resonances, such as NAA and N-aceylaspartylglutamate (NAAG) often seen in in vivo spectral data. In addition, LCModel estimates a baseline for short echo time spectra, which includes macromolecules with short T2 relaxation times making a fit of the lower concentrations and overlapping (20) . Metabolite concentrations with a SD% of 25 or less were included in the study. Differences between in vivo and in vitro T2 relaxation times were not taken into account since these corrections would be small and overly time-consuming to incorporate into a clinical study. T1 saturation effects can be ignored since long repetition times were used for all acquisitions. The following metabolite ratios were also calculated: NAA/Cre, NAA/Cho, Cho/Cre, mI/Cre and Glx/Cre. Data analysis. For all TBI patients, we used a nonparametric Mann-Whitney test to determine significant differences between the means of good outcome patients versus poor outcome patients for clinical and imaging data using the SPSS Statistics for Windows (SPSS Inc., Release 10.0, Chicago, IL). A one-way analysis of variance (ANOVA) with a post hoc Scheffe test was used to compare spectroscopy variables in the control group to the good and poor outcome TBI groups. Differences were considered significant at p Յ 0.05. Correlations between mI and Glx in gray and white matter to clinical and other spectroscopy variables were reported as Spearman rho correlation coefficients with significance at p Յ 0.05. A logistic regression analysis was also performed to determine which spectroscopy variable alone or in combination with clinical variables best predicted the correct long-term dichotomous outcomes. The analysis assigns weighting factors to each variable. A large weighting factor means that the variable is strongly predictive of outcome. In this way, we were able to determine which variables were prognostic and should be used in the analysis. Table 1 summarizes clinical data on the dichotomized outcome groups (good, n ϭ 29; poor, n ϭ 9). Patients with poor outcomes had lower GCS scores, a longer duration of coma and more days of ventilator support. They also had evidence of more severe DAI as manifested by a greater number and volume of hemorrhagic lesions detected by show that children with TBI with either good or poor (n ϭ 38) outcomes had higher occipital gray matter (OGM) mI levels than controls (n ϭ 10) (*p ϭ 0.003). Also patients with poor outcomes (n ϭ 9) had higher OGM mI levels than those with good outcomes (n ϭ 29) (**p Ͻ 0.05). No differences between controls and good vs. poor TBI patients were seen in the parietal white matter (PWM). Results for the myoinositol/creatine (mI/creatine) ratios (B) show no differences in either OGM or PWM between the three groups.
RESULTS

Clinical data.
MRI. There were no differences between groups for the serum sodium or glucose levels measured initially or on the day of MRS. In addition, the average cerebral perfusion pressure (intracranial pressure -mean arterial pressure) for the first day of ICP monitoring was not significantly different between groups.
MRS data. Figure 1 demonstrates SWI images (A) and a MRS spectrum (B) from a patient with a good outcome who has normal metabolite and mI peaks. Figure 2 shows imaging and spectral data from a patient with a poor outcome who had a reduced NAA and an elevated mI peak. Table 2 summarizes data for all metabolite levels and ratios in normal appearing brain. Quantitative Glx and mI levels in OGM were significantly higher in children who suffered TBI compared with controls. We found no significant difference in Glx for patients with good outcomes compared with those with poor outcomes, however, mI was significantly higher for patients with poor outcomes (p Ͻ 0.05) (Fig. 3A) . We found no significant differences in quantitative PWM Glx or mI levels and no significant differences in metabolite ratios for either location (Table 2 and Fig. 3B ).
OGM and PWM NAA/Cre and NAA/Cho ratios were lower in TBI patients compared with controls. In addition, the NAA/ Cre in both regions were lower in poor compared with good outcome patients. Based on the quantitative MRS data, these ratio changes were due to both higher Cre and to lower NAA levels (which reached significance in PWM but not OGM) that occur after TBI. Table 3 summarizes the Spearman Rho correlation coefficients and p values for selected clinical and spectroscopy values for OGM and PWM quantitative Glx and mI values. OGM mI levels correlated with duration of coma, days on ventilator, days in hospital, volume of SWI lesions and 6 -12 mo outcome, whereas, Glx levels did not. Significant linear correlations were observed in OGM and PWM between mI, Glx, and Cre. Table 4 summarizes results of the logistic regression analysis. Clinical variables (GCS score, number of days in coma or on ventilator) alone or in combination correctly predicted outcome in 76% to 82% of cases, however, none of the predictions were significant. The total number and volume of hemorrhagic DAI lesions as measured with SWI correctly predicted outcome in 79% of patients and different combinations of the MRS variables predicted outcome in 79% to 82% of outcomes. Although several MRS variables alone or in combination correctly predicted a high percentage of outcomes, only a few approached significance using a 2 test. For example, OGM mI alone correctly predicted outcome in 79% (p ϭ 0.07) of patients with 1/29 false positive cases (i.e., poor outcome predicted but good outcome occurred) and 6/9 false negative cases (i.e., good outcome predicted but poor outcome occurred) and OGM Glx alone predicted 79% (p ϭ 0.11) with no false positive cases. For comparison, OGM NAA and Cre predicted 76% (p ϭ 0.70) and 79% (p ϭ 0.39), respectively with 100% false negative cases for NAA. By combining several OGM MRS variables (Cre, mI and Glx), the predictive accuracy increased to 82% with p ϭ 0.08. Combining neuroimaging or clinical variables with MRS also tended to increase the number of correct predictions, but the measurements were not significant. In addition, metabolite ratios were also tested and were found to be less predictive. Therefore, it appears that using MRS levels (particularly from OGM) alone or in combination tended to produce the best results.
DISCUSSION
Myoinositol was first isolated as a chemical compound in 1850 and later found to be one of nine stereoisomers of the compound hexahydroxycyclohexane (7) . Myoinositol is the most common of these stereoisomers and is conventionally inferred when the term inositol is used. In humans, mI content is greatest in the kidneys, brain, and testes. Dietary sources shown since the 1940s that inositol lipids are highly metabolically active and, more recently, that they are components of a phosphoinositide-mediated signal transduction system. The concentration of mI in neural cells is about 2 to 500 times that of plasma-a gradient for which a high affinity sodium-mI transporter (SMIT) is responsible. SMIT mRNA and protein expression are highest in the fetal brain, a fact reflected in the high concentration of mI in fetal CSF (21) and in the newborn brain (8) . In fact, mI is the largest peak seen in proton spectra from normal newborn brain (22) . A second pH sensitive mammalian mI transporter (Hϩ/myo-inositol symporter; HMIT) has also recently been identified (23) . In addition to synthesis and active transport of mI, a third primary method of cellular mI regulation is facilitated diffusion, responsible for mI efflux in neurons and glia (7) . It should also be noted that mI seen spectroscopically represents free rather than bound intracellular mI rather than extracellular mI (24) . Myoinositol and previous MRS studies. Several previous investigations in adults have reported on mI ratios after TBI. In one study of 26 patients, scanned 12 d postinjury, MRS from normal appearing posterior frontal white matter had increased mI/Cre (mI reported as Ins) as well as decreased NAA/Cre and increased Cho/Cre (25) . The increases in mI and Cho observed in this study were considered reflective of glial cell proliferation. A second study reported spectral data of serial MRS 
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examinations in 19 adult patients at 1.5, 3, and 6 mo (3). Myoinositol (reported as mIs) in gray matter was increased at 6 mo compared with controls whereas mI in white matter was increased at 1.5 and 6 mo. Cognitive function testing, done at the time of MRS, showed a correlation at 1.5 mo between mI and cognitive outcome but not at 3 or 6 mo. Studies of mI after pediatric TBI have not been previously reported.
The results of the logistic regression analysis demonstrate that in children as in adults, MRS variables are predictive of outcome. In particular, MRS variables used alone or in combination resulted in correctly predicting outcome in 79 to 82% of the cases. This was similar to clinical and neuroimaging variables, however, only the results using MRS variables approached significance. Our results show that one can improve the ability to predict outcome after serious TBI in children (5, 6) and in the present study, mI was useful for this purpose.
Astrogliosis. The reason for the increase in mI observed in our patients is unknown but astrogliosis is suspected. It is well known that astrogliosis (increased astrocyte number and activity) begins soon after TBI and can persist for weeks to months (9) . Several previous MRS studies have supported the idea that increases in mI reflect an increase in glial content or glial proliferation (2, 3, 26) . Reports in patients with multiple sclerosis during the acute stages of demyelination due to the accumulation of myelin breakdown products as well as in chronic inactivated demyelinated lesions have revealed elevated mI attributed to astrocytosis (27) . Although the pathophysiology of multiple sclerosis differs from TBI, these findings lend indirect support to our observation that the increase in mI in our patients was due to a combination of acute accumulation of DAI-associated myelin breakdown products and the later development of astrocytosis.
More recent studies in a rat brain contusion model also support our belief that increased mI after TBI is due to astrogliosis. Although mI decreased initially in these experimental studies, it was increased by 31% seven days after injury, the same time frame that our MRS studies were performed, although the time frame in animal models may be different from that observed in human TBI (28) . These findings in the rat brain correlated with a substantial increase in two markers of astrocytic activity: a diffuse increase in glial fibrillary acidic protein immunohistochemical staining and an increase in the number of vimentin-positive astrocytes. These findings also were correlated with an increase in choline and were interpreted as a reflection of glial activation.
Of interest is that in our study, outcome correlated with OGM but not with PWM mI levels ( Table 2 ). In one report in adults, mI was greater in PWM but not OGM at 1.5 mo but by 6 mo both regions showed increased mI compared with controls (3). Another study also looked at early (i.e., 12 d) versus. late (6 mo) mI data but only in frontal white matter and found increased mI (25) . The fact that the majority of astrocytes are located near cortical gray matter neurons, rather than in white matter, may explain why we found that outcome correlated with OGM mI levels but not with PWM mI levels. As our spectra were obtained from occipital gray matter 7 d (range 1-17 d) postinjury, the differences between our results and those in adult TBI patients suggest the need for additional studies to determine whether these differences are age or time dependent.
If posttraumatic astrogliosis interferes with neural repair mechanisms and axonal regeneration, the presence of elevated mI as a marker of astrogliosis may be clinically important as a variety of experimental approaches to reduce astrogliosis are currently under investigation and eventually could be applied to patients. These include astrocyte ablation, transgenic approaches to reduce extracellular matrix formation, attenuation of factors stimulating astrogliosis, inhibition of mediators of the posttraumatic inflammatory response, gene manipulation of astrocyte function, etc (9). 
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Osmolyte regulation. A second reason for increased mI may relate to its role as an osmolyte. Cerebral edema is common after TBI and DAI and can be vasogenic, due to breakdown of the blood-brain barrier to macromolecules, and cytotoxic, due to disturbed cell metabolism. Disruption of the blood brain barrier leads to extravasation of proteins and other osmotically active molecules. As a protective response, mI levels are increased by several mechanisms, including the up-regulation of SMIT mRNA (29) . Separately, cytotoxic injury can occur after TBI, as is commonly associated with focal ischemia and stroke. Myoinositol transport has been shown to be diminished after stroke (30) . A rise in intracellular electrolytes and accumulation of osmotically active catabolites would normally be balanced by mI efflux. Because of diminished ATP, required for the volume-sensitive organic osmolyte anion channel, mI efflux is diminished and results in neuronal swelling (7, 31) . Neuropathological studies have also found that diffuse edema is common in patients with DAI (32) .
In our patients, the role of mI in osmotic balance may have been influenced by the administration of hypertonic saline for treatment of increased ICP. In the face of hypernatremia the brain accumulates mI to decrease water loss (7, 33, 34, 35) . In addition, if hypernatremia is corrected too rapidly, the sudden change in osmotic gradient may lead to massive cerebral edema. Of our 38 patients, 21 had ICP monitoring based on the severity of their injury and initial neuroimaging findings. Of these individuals; 17 had elevated ICP. Although 27 of our 38 patients received hypertonic 3% normal saline to control ICP or for other clinical reasons (e.g. pupillary changes in patients who were not being monitored), we found no correlation between serum sodium levels, either initially or on the day of MRS, with either OGM or PWM mI levels (Table 3) . We also did not observe any correlation between ICP and OGM or PWM mI levels.
Glutamate. In one recent study of children with different forms of TBI, early measurement of CSF glutamate was found increased in children less than four years of age primarily with nonaccidental trauma and correlated with outcome (14) . Older children with TBI due to pedestrian versus motor vehicle accidents did not show a consistent increase in glutamate nor was there a correlation with outcome. A trend toward an association between high glutamate concentrations and ischemic blood flow was also observed. The Glx peak, which is a combination of glutamate, glutamine and GABA (gamma-amino-butyric acid), was increased in all of our TBI patients, not just those with poor outcome. Although Glx levels did not correlate with outcome, they did correlate with the mI levels.
Glutamate may increase cell swelling and presumably this may also increase mI (36) . In the current study, MRS was performed on average 7 d after injury, suggesting that there may be prolonged glutamate release which may contribute to the severity of injury by several mechanisms and in part could be mediated by glutamate induced increases in mI. Glutamate increases, if extracellular, may reflect greater primary axonal injury and transmitter leakage or greater secondary neuronal and glial energy failure and free-radical injury, with neuronal depolarization, Caϩϩ increases, or decreased glial transmitter reuptake.
Overall the findings from out study and those involving CSF glutamate measurements suggest that the role of glutamate after TBI in children remains unclear and could be affected by the age of the patient, the nature and severity of injury, the association of secondary ischemic injury and presumably other variables.
Other mechanisms. Intracellular calcium is also important in the regulation of mI content (7) . Recent investigations in a stretch-injured astrocyte model has found that such injury results in a rapid increase of intracellular Ca ϩϩ and also that intracellular calcium stores were no longer able to release Ca ϩϩ in response to inositol triphosphate (IP3) (37) . This suggested that IP3 uncoupling might contribute to pathologic alterations and further brain injury. In our patient population, with the degree of DAI that we observed, stretch injury likely occurred and could have resulted in increased intracellular Ca ϩϩ. This may be another mechanism that contributed to the increase in mI and the correlation between mI and the number and volume of SWI lesions.
CONCLUSIONS
The finding that mI is increased in children with TBI and that it correlates with long-term outcome is intriguing. It may serve as a marker for posttraumatic astrogliosis or perhaps reflect disturbances in osmotic regulation. In either case, spectroscopic monitoring of mI in patients with TBI may be helpful and potentially could be used as a biochemical marker of the development of astrogliosis and of treatment.
